BioXcel Therapeutics

10:30 AM - 10:45 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
BioXcel Therapeutics is a clinical stage biopharmaceutical company focused on drug development in neuroscience and immuno-oncology utilizing artificial intelligence. Currently the company has two lead clinical development programs:
o BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders
• Reported positive results from Phase 1b trial of intravenously-dosed Dexmedetomidine supporting BXCL501 development in schizophrenia
• Data from Phase 1b PK/PD safety study in mild probable Alzheimer’s patients expected in second half of 2018
o BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer
• Announced FDA acceptance of IND for treatment emergent neuroendocrine prostate cancer; study expected to be initiated in fourth quarter of 2018
• Entered clinical partnership with Nektar for study in pancreatic cancer
Ticker:
BTAI
Exchange:
Nasdaq
Company Type:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
BXCL501 and BXCL701
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided